Dyspnea affective response: comparing COPD patients with healthy volunteers and laboratory model with activities of daily living

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters

Citation
O’Donnell, Carl R, Richard M Schwartzstein, Robert W Lansing, Tegan Guilfoyle, Daniel Elkin, and Robert B Banzett. 2013. Dyspnea affective response: comparing COPD patients with healthy volunteers and laboratory model with activities of daily living. BMC Pulmonary Medicine 13:27.

Published Version
doi:10.1186/1471-2466-13-27

Citable link
http://nrs.harvard.edu/urn-3:HUL.InstRepos:11181051

Terms of Use
This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Dyspnea affective response: comparing COPD patients with healthy volunteers and laboratory model with activities of daily living

Carl R O'Donnell1,2*, Richard M Schwartzstein1,2, Robert W Lansing1, Tegan Guilfoyle1, Daniel Elkin1 and Robert B Banzett1,2

Abstract

Background: Laboratory-induced dyspnea (breathing discomfort) in healthy subjects is widely used to study perceptual mechanisms, yet the relationship between laboratory-induced dyspnea in healthy volunteers and spontaneous dyspnea in patients with chronic lung disease is not well established. We compared affective responses to dyspnea 1) in COPD patients vs. healthy volunteers (HV) undergoing the same laboratory stimulus; 2) in COPD during laboratory dyspnea vs. during activities of daily living (ADL).

Methods: We induced moderate and high dyspnea levels in 13 COPD patients and 12 HV by increasing end-tidal CO2 (PETCO2) during restricted ventilation, evoking air hunger. We used the multidimensional dyspnea profile (MDP) to measure intensity of sensory qualities (e.g., air hunger (AH) and work/effort (W/E)) as well as immediate discomfort (A1) and secondary emotions (A2). Ten of the COPD subjects also completed the MDP outside the laboratory following dyspnea evoked by ADL.

Results: COPD patients and HV reported similar levels of immediate discomfort relative to sensory intensity. COPD patients and HV reported anxiety and frustration during laboratory-induced dyspnea; variation among individuals far outweighed the small differences between subject groups. COPD patients reported similar intensities of sensory qualities, discomfort, and emotions during ADL vs. during moderate laboratory dyspnea. Patients with COPD described limiting ADL to avoid greater dyspnea.

Conclusions: In this pilot study, we found no evidence that a history of COPD alters the affective response to laboratory-induced dyspnea, and no difference in affective response between dyspnea evoked by this laboratory model and dyspnea evoked by ADL.

Keywords: Dyspnea, Symptom assessment, COPD

Background

How well do laboratory models contribute to our understanding of clinical dyspnea? Dyspnea is defined by the American Thoracic Society as “...a subjective experience of breathing discomfort that consists of qualitatively distinct sensations that vary in intensity. The experience ... may induce secondary physiological and behavioral responses” [1]. This shares features with definitions of pain, which has been described as “an unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage” [2]. In the development of pain theory the affective dimension of pain has been divided into an initial stage (A1) of ‘immediate unpleasantness or discomfort’ and a later stage of emotional outcomes (A2) that may lead to behavioral outcomes [3-6]. The affective response to either pain or dyspnea can vary independently of sensory intensity [7,8] Thus, both dyspnea and pain are understood to have sensory and affective dimensions and, in pain theory, it is accepted that laboratory models have contributed to a better understanding of neurophysiological mechanisms and treatment [9].
As is the case with pain models, a multidimensional perspective on dyspnea may also be useful for addressing question about the transferability of laboratory models to practice. A customary single-dimension measure of dyspnea, such as use of a modified Borg scale to rate sensory intensity (SI), may not adequately assess the differences seen between clinical and laboratory dyspnea. Although SI may predict affective response, the relationships among SI, A1 and A2 are likely to be influenced by factors such as sensory quality (SQ), pathophysiology, and environment. Thus, while laboratory models have been valuable in defining neural mechanisms of dyspnea, and in testing potential palliative interventions, they are prone to the criticism that clinical dyspnea is fundamentally different than laboratory dyspnea and that the experience of patients greatly alters their perceptual and emotional responses [11-14]. For example, laboratory interventions probably stimulate only a subset of the sensory receptors activated by pathophysiological processes and may give rise to different qualities of sensation. There are differences between the psychological environment of the laboratory and daily life: knowing that experimental risks are minimal, and that one can stop an experiment at any time, might reduce fear and anxiety compared to dyspnea associated with disease conditions that cannot be controlled.

In this study, we tested the extent to which one laboratory model of dyspnea (air hunger) evokes different affective responses between COPD patients and HV. We also assessed differences in affective responses of COPD patients to the lab dyspnea model and dyspnea associated with activities of daily living (ADL). Using a multidimensional measurement instrument that incorporates qualitative and affective measurements, we first compared dyspnea perceptions of Healthy and COPD volunteers in the laboratory [15]. We, then compared dyspnea perception in the laboratory with dyspnea perception in the daily lives of the same COPD volunteers. We tested three statistical null hypotheses:

**H0_1** During experimentally induced dyspnea, the relationship between immediate affective response (unpleasantness, discomfort or A1) and the intensity of specific sensory qualities (SI) does not differ between healthy and COPD volunteers.

**H0_2** During experimentally induced dyspnea, the relationship between immediate unpleasantness, discomfort and emotional affective response (A2) does not differ between healthy and COPD volunteers.

**H0_3** In individuals with COPD, the relationship between immediate unpleasantness, discomfort and emotional affective response does not differ between dyspnea associated with activities of daily living (ADL) and experimentally induced dyspnea.

**Methods**

**Subjects**

Subjects at least 45 years old were recruited through advertisement and referral by pulmonary physicians. We screened subjects for self-reported cardiopulmonary or neurological conditions, and administered the Baseline Symptom Inventory (BSI-18) to identify subjects prone to panic disorder [16]. No subjects were excluded based on BSI results. In order to assure comparable baseline (pre-stimulus) measurement conditions between COPD and healthy volunteers, we selected COPD participants who reported dyspnea during exercise but not at rest. COPD diagnosis was confirmed by pulmonary function tests (PFTs) and compatible history and symptoms [17,18]. Healthy volunteers reported no history of physician-confirmed COPD, no use of respiratory medication, and no exercise limitation due to respiratory symptoms. Prior to each experimental day, subjects were asked about acute changes in health status such as respiratory infections, COPD exacerbation, and change in medication type or dose. The study protocol was approved by the Committee on Clinical Investigation of the Beth Israel Deaconess Medical Center, where all experiments were performed (Protocol # 2006P000468). All subjects gave written informed consent.

**Physiologic measurements**

Subjects began each session by sitting comfortably and reading a standard text while end-tidal PCO2 (PETCO2) was sampled in one nostril through an unobtrusive tube. During experiments, subjects breathed through a mouth-piece; tidal PCO2 and pressure at the airway opening were sampled in the common line, and we monitored pulse rate, arterial oxygen saturation and blood pressure throughout the experiment. Data were digitized and recorded for later analysis (PowerLab 16/30, AD Instruments, Colorado Springs, CO).

**Stimulus and protocol**

Using a standardized script (see Additional file 1, text of standardized script), we instructed subjects on the details of the experimental protocol. On separate practice days, we familiarized subjects with the dyspnea experience to stabilize the relationship between stimulus and rating and to identify subjects who were unable to provide ratings reliably related to stimulus level [19]. Five unreliable raters (2 HV, 3 COPD) were excluded. These excluded subjects all had R² value <0.49 (R < 0.7) for the regression of
During laboratory dyspnea challenge, subjects continuously rated 'breathing discomfort' (BDVAS) on P_{ET}CO_2.

We employed a hypercapnic stimulus with minute ventilation constrained to 0.13 liters/min/kg (termed here 'standard ventilation', a level modestly greater than normal resting ventilation), by limiting flow to an inspiratory reservoir bag (see figure in Additional file 2 schematic of hypercapnic stimulus apparatus and on-line rating device). To control frequency and tidal volume, subjects breathed at 14 to 16 breaths per minute in time with an audible signal. The standard ventilation was achieved by all subjects with no evidence of dynamic hyperinflation. Stimulus strength, i.e., change in P_{ET}CO_2 above resting value, was varied 3 to 5 times in an arbitrary pattern to minimize subject expectation [20]. At each step, the goal was to achieve a constant P_{ET}CO_2 for 2 minutes. We used continuous on-line ratings to target experimental endpoints of moderate and high levels of breathing discomfort (A1) (60% and 90% full scale [FS]).

Each test lasted approximately 15 minutes, and subjects completed a minimum of one test concluding at each of the two targeted end-points (moderate and high discomfort) The Multidimensional Dyspnea Profile (MDP) was completed immediately after each test, and subjects were instructed to focus on the final 30 to 60 seconds of the stimulus exposure (corresponding to the targeted endpoint). Physiologic data associated with MDP ratings were averaged over the same 30 to 60 seconds.

Measurement of dyspnea

During laboratory dyspnea challenge, subjects continuously rated 'breathing discomfort (BD), or unpleasantness' using an online 'Visual Analog Scale' (BDVAS) anchored with "No Discomfort" at 0 and "Stop Now" at 100% of full scale (%FS). The experimenters immediately reduced the stimulus if the subject rated 100%. The BDVAS was intended as a continuous measure of A1 (immediate discomfort), and was used to target comparable levels of A1 among subjects prior to completion of the MDP (see Additional file 2).

Following each laboratory dyspnea challenge, and following periods of activity at home, subjects reported respiratory sensations and resulting emotional responses using the Multidimensional Dyspnea Profile (MDP) [8,15]. Respondents rated items on 10 point visual analog scales (VAS) related to: perceived overall sensory intensity (SI); immediate unpleasantness of the dyspnea experience (immediate affective response or A1); the intensity of specific sensory qualities (SQ) such as a sense of "air hunger" and "breathing work and effort" [21-23] and emotional responses such as fear, anxiety and frustration (secondary affective response, A2). Respondents also chose a single SQ that most aptly described the dyspnea sensation. (See Additional file 3 for a schematic representation of the MDP) The MDP, which can be completed in 2–4 minutes, is designed for both laboratory and clinical use, and can be administered immediately following an event or used for later recall. The construct validity, responsiveness and reliability of this instrument have been described [15].

Protocol for dyspnea assessment during activities of daily living

After completing all laboratory experiments, COPD patients took home copies of the MDP to complete daily for 2 weeks following episodes of dyspnea associated with normal Activities of Daily Living (ADL). Patients also recorded the events that had provoked the reported dyspnea. MDP responses were averaged within subject to provide equal weighting, and were then compared to responses obtained from the same subjects following laboratory dyspnea.

Statistical analyses

Descriptive statistics by subject type and stimulus intensity are reported as means and standard deviations. The statistical significance of between group (Healthy vs. COPD) item response differences was evaluated by the Mann-Whitney U test, while the Wilcoxon test was used to evaluate within group (by stimulus intensity) differences. Repeated measures ANOVA was used to assess group by stimulus intensity interactions. Additional analyses to assess internal consistency and test-retest reliability of the MDP in a laboratory setting are provided in Additional file 4 (MDP test-retest measures). Statistical analyses were performed using SPSS version 12.0.1.

Results

Subjects

Analyses were performed on 12 HV and 13 COPD patients whose characteristics are shown in Table 1. (See Additional file 5 for detailed subject data) We assessed the effect of stimulus strength using data from 11 HV and 12 COPD patients, for whom MDP responses were available at both moderate and high unpleasantness ratings. We assessed test-retest reliability of the MDP in nineteen subjects (12 COPD, 7 Healthy) who gave BDVAS ratings during the final minute of the laboratory stimulus on separate days that matched within 10% full scale (Additional file 4). Home MDP data were collected from 10 of the COPD patients who had been tested in the laboratory.

Laboratory challenge: COPD patients vs. HV

As would be expected from the similarity in underlying constructs, on-line BDVAS corresponded closely to subsequent MDP ratings of A1 (mean difference 2.5% FS; R^2 = 0.704). There was no significant difference by subject type (p = 0.80 by two way ANOVA of subject
type and stimulus level, (see Additional file 6 scatter plot of A₁ vs. BDVAS by subject type).

The stimulus levels (increase in PETCO₂ above resting) that evoked moderate (healthy 5.5 ± 3.7, COPD 2.8 ± 3.8) and high (healthy 10.5 ± 4.5, COPD 6.4 ± 7.5) ratings were not significantly different between subject groups (P = 0.18), and mean BDVAS and A₁ were equivalent at both stimulus levels (Figure 1).

Choice of sensory quality descriptors: COPD patients vs. HV

The set of descriptor phrases “I am not getting enough air, I feel hunger for air, or I am smothering” was chosen as the best descriptor by 52% of subjects following moderate, and 65% of subjects following high laboratory stimulus presentations. We term this descriptor group air hunger (AH). The descriptor phrase “I feel that my breathing requires work or effort” (WE) was chosen as the best descriptor by 35% of subjects following moderate and 22% of subjects following high laboratory stimulus presentations. All other descriptor phrases, such as “my chest or lungs feel tight”, or “I am breathing a lot” were chosen as best descriptor by only 13% of subjects following laboratory stimulus presentations. Best descriptor choice did not differ significantly between COPD and healthy subjects.

Despite discrimination of best descriptor choice at both stimulus levels, subjects provided roughly equal scale ratings of both sensory qualities; this apparent contradiction is discussed below. Following stimulus exposure at the moderate level, subjects rated AH at 46% full scale compared with 57% for WE (p = 0.035). Following exposure at the high level, corresponding ratings were 83% versus 86% (p = 0.223). Sensory quality ratings did not differ significantly by subject type.

Unpleasantness and global sensory intensity responses: COPD patients vs. HV

A₁ differed significantly between levels of perceived sensory intensity, (p < 0.001). We compared A₁ ratings between groups at roughly matched levels of air hunger. There were no significant differences in mean ratings of A₁ between healthy and COPD patients (by repeated measures ANOVA, p = 0.448). To account for small differences in sensory intensity within level, we plotted mean A₁ versus mean ratings of AH by stimulus level and subject type (Figure 2).

Emotional response to laboratory dyspnea: COPD patients vs. HV

Both HV and COPD patients rated appreciable levels of “anxiety” and “frustration” related to laboratory exposure to the dyspnea challenge (Table 2). These emotions increased significantly at higher stimulus intensity (by repeated measures ANOVA, p < 0.001 for anxiety and p = 0.003 for frustration). However, there was no significant difference in emotional response between HV and COPD patients (Figure 3). For difference in rating by subject type (controlling for stimulus level), p = .321 and .952 for anxiety

---

**Table 1 Subject characteristics**

|                | N male (%) | Age* | Height (cm) | Weight (kg) | BMI (kg/m²) | BSI-18 | Resting PETCO₂ (mmHg) | GOLD stages | FEV₁/FVC | FEV₁ (%Pred) |
|----------------|------------|------|-------------|-------------|-------------|--------|----------------------|-------------|----------|-------------|
| COPD           | 7 (54%)    | 67.5 | 171.8       | 80.8        | 27.5        | 6.2    | 37.8                 | III 5       | 58.4     | 46.9        |
| N = 13         | (7.8*)     | (8.8) | (22.1)      | (7.9)       | (6.1)       | (1.8)  | (22.1)               | II 6        | (15.8)   |
| Healthy        | 8 (67%)    | 54.8 (4.8) | 172.2   | 77.3       | 25.9        | 2.1    | 40.0                 | 1 2         |          |
| N = 12         | (46–61)    | (10.8) | (13.8)     | (2.8)       | (3.6)       | (2.8)  |                      |             |          |

*P < 0.001 by Mann–Whitney U for difference between healthy and COPD subjects.

*SD.

*(range).
and frustration respectively. Both HV and COPD patients rated anger and depression less than 10% FS following stimulus exposure.

Laboratory dyspnea vs. dyspnea of daily living (subset of 10 pts)
Ten COPD patients completed take-home dyspnea instruments. An average of 14 MDPs were completed by each subject following a separate instance of dyspnea over the course of two to three weeks. Fifty-one percent of 140 subject reports indicated that dyspnea episodes occurred while walking or climbing stairs, often when carrying groceries, laundry etc. Forty-eight percent of reports indicated that subjects curtailed the intensity or duration of ADL in order to limit dyspnea. Unfortunately the layout of the self-completed MDP used in this study failed to focus the subject’s attention on the requirement to choose the best descriptor, thus best-descriptor data were insufficient for analysis.

Table 2 A2 responses of healthy volunteers and COPD patients to moderate and high laboratory stimuli

| Stimulus level | Subject type | Anxious | Frustrated | Afraid |
|----------------|--------------|---------|------------|--------|
| Moderate       | Healthy      | 20.0* (5.8) | 14.2 (6.0) | 5.9 (3.2) |
|                | COPD         | 27.6 (6.3)  | 19.7 (5.2) | 12.8 (5.1) |
| High           | Healthy      | 40.5 (11.0) | 39.0 (8.6) | 18.6 (7.7) |
|                | COPD         | 54.2 (9.4)  | 33.3 (8.7) | 30.4 (10.0) |

Ratings are given as % full scale ± se.

Relationship of A1 to sensory intensity during ADL in COPD patients
The relationship between A1 and perceived air hunger was remarkably similar between ADL and the laboratory. Serendipitously, average A1 ratings associated with ADL were close to those earlier reported by the same subjects following the arbitrarily targeted moderate level of laboratory stimulus (Figure 4). This allows comparison of the other dimensions of dyspnea with reasonable confidence that non-linearity is not an issue.

The ratings of SQ during ADL were not significantly different than ratings obtained during the moderate level laboratory stimulus.

Emotional response during ADL in COPD patients
The anxiety or frustration associated with respiratory discomfort was nearly the same whether the dyspnea was experienced during ADL at home or during moderate level laboratory stimulus (Figure 5). Subjects rated both anxiety (5a) and frustration (5b) at approximately 20% FS, about the same as during the moderate laboratory stimulus (p > 0.5).

Discussion
Summary conclusions
These are the first observations comparing multiple aspects of the dyspnea experience of HV and COPD patients following exposure to a laboratory dyspnea challenge that is physiologically equivalent in the two groups. Exercise has different physiologic implications for respiratory function in COPD, especially tidal volume limitation because of dynamic elevation of FRC [24,25], resulting in different qualities of dyspnea sensation and affective response [22]. Consequently, we selected a stimulus that evoked dyspnea without increased ventilation in an attempt to provoke the same sensation in both groups.

Our results are consistent with the three null hypotheses proposed: 1) COPD patients and HV report similar unpleasantness for a given intensity of sensation (AH and WE) in laboratory experiments; 2) COPD patients and HV reported similar emotional responses during laboratory dyspnea; 3) COPD patients reported similar frustration and anxiety with ADL as they did with laboratory dyspnea.

Given the modest sample size, we consider below whether any important differences are likely to have gone undetected by this study (‘Type II error’).

Do patients with chronic lung disease have a different affective response to dyspnea?
We showed that COPD patients and HV undergoing the same laboratory dyspnea experience report the same quality of sensation and the same immediate unpleasantness. This implies that long experience to clinical dyspnea has
not greatly altered the immediate processing of respiratory discomfort. This is consistent with findings in competitive breath-hold divers whose perception of laboratory air hunger is not different from normal subjects [26].

We observed that the emotional component of dyspnea differed widely among individuals at both moderate and high strength laboratory stimulus levels (see graph in Additional file 7, interindividual variability of anxiety ratings (A2) following moderate and high level stimulus exposure). This type of individual difference in the emotional response to unpleasant stimuli has been termed affective style, and is likely an individual characteristic [27]. This affective style, captured by the MDP, may contribute to differences in clinical expression of symptoms and, ultimately, influence whether a particular individual seeks medical care for her symptom [15].

In COPD patients, does the affective response to laboratory dyspnea challenge differ from the affective response to dyspnea in daily life?

COPD patients reported episodes of dyspnea during ADL that were similar in intensity and unpleasantness to our moderate strength laboratory dyspnea challenge. Ratings of anxiety, frustration and fear were in the lower third of the scale. Patients frequently reported that they limit physical activity in daily life to avoid high dyspnea levels, probably to avoid discomfort and adverse emotions. The relatively low A2 ratings may reflect a sense of control during daily activity. At higher levels of laboratory stimulus, ratings often exceeded 50%FS, but, probably because subjects were also in control of the maximal stimulus, anxiety ratings seldom reached 100%. This contrasts with emotional responses to dyspnea in acutely ill patients with inescapable dyspnea. For example, as noted by one patient after rating A1 at 75% FS and anxiety at 50%FS, “if I was alone and breathing like this I would be scared, would definitely feel more afraid [at home] not knowing how long it will last”. This is consistent with reports from patients seeking treatment in an emergency room [13].

Limitations of this study

Sample size

We studied a relatively small number of subjects, thus the lack of statistically significant differences may reflect Type II errors. What is the likelihood that Type II errors could have obscured functionally important differences?
The mean differences we report between affective responses by subject type (healthy vs. COPD) is virtually nil at moderate stimulus, and at most 14% FS at high stimulus for anxious (see Figure 3). Based on current data our best estimate is that anxiety in COPD patients during laboratory stimuli is very similar to healthy controls. However, because variance was large (coefficient of variation >60% for both HV and COPD patients), we can not state with confidence that anxiety in COPD is less than 20% FS different from controls following exposure to high intensity laboratory stimulus. Even this worst-case estimate would not be large enough to invalidate the use of the air hunger laboratory model for investigation of dyspnea. As described above, the large SD was mainly attributable to inter-, rather than intra-, individual variation of emotional responses in both subject groups. Repeat assessment in the laboratory (see Additional file 4) and clinical setting demonstrate intradividual consistency of affective ratings using the MDP. Thus, the effect of individual psychological characteristics seems to overwhelm the effect of chronic respiratory disease on the emotional response to dyspnea.

Sample characteristics
COPD patients (67.5 ± 7.8) were older than healthy volunteers (54.8 ± 4.8). We found no reports of age associated differences in dyspnea perception during well-controlled stimulus exposure among adult subjects who differ in age by 10 to 15 years. Indirect evidence of age associated differences comes from studies of resistive load threshold detection among older asthmatics [28,29]. As we selected a stimulus not directly affected by mechanical load, we don’t think this evidence is relevant to interpretation of our results. To affirm this conclusion, we selected the 6 (50%) healthy volunteers (ages 56–61) and 8 (66%) COPD patients (ages 56–67) with overlapping age ranges. As in the larger groups, results for this subset were similar between subject types.

Ability of MDP to discriminate sensory quality
There was a clear favorite choice of descriptor that best characterized the sensation during laboratory dyspnea, yet there was considerable overlap in the ratings of descriptors on a scale from 0–10. Our interpretation of this is that when subjects are presented with several parallel rating scales, many tend not to greatly separate ratings. On the other hand, when forced to make a choice about the most prominent sensation, the subject makes a judgment. As expected from results in earlier studies that exposed subjects to a similar dyspnea stimulus [8], air hunger was the best descriptor. In addition, high ratings of ‘work effort’ may reflect a combination of respiratory muscle effort and mental effort. Subjects presented with the supplementary descriptor “my breathing required concentration or mental effort” rated this item 62%FS and rated muscle work 56%FS.

$P_{ET}\text{CO}_2$ measurement
The average changes from resting ($\Delta P_{ET}\text{CO}_2$) associated with the BDVAS ratings differed somewhat between COPD patients and HV, although the difference was not statistically significant. In COPD, $P_{ET}\text{CO}_2$ is not a reliable indicator of arterial blood gases due to heterogeneous ventilation/perfusion ratio, the effect of which causes $P_{ET}\text{CO}_2$-$Pa\text{CO}_2$ difference to vary with tidal
volume, T_E, and PICO2-PaCO2 difference. Furthermore, ratings of SI for a given ΔPCO2 is known to vary widely among individuals [30]. For these reasons we chose to match stimulus strength based on on-line ratings, not on ΔPCO2. Because the range of ΔPCO2 was modest, approximately 2–10 mmHg, symptoms and signs attributable to elevated PaCO2, such as headache, elevated blood pressure and flushing, did not appear to affect discomfort ratings.

Conclusions and implications

Our laboratory dyspnea model can produce sensory and affective responses in both HV and COPD patients similar to those experienced by COPD patients during exertion. Furthermore, similar sensory and affective responses are evoked in both healthy subjects and those with chronic disease. The laboratory intervention is capable of producing much stronger responses than moderately impaired COPD patients ordinarily allow themselves to experience during ADL, thus the laboratory intervention can be adjusted to match a wide range of clinical severity. We conclude that, despite very real differences between laboratory and clinical settings, laboratory results obtained by studying healthy individuals can be useful in examining mechanisms and testing treatments for patients with lung disease.

Our results carry implications for future dyspnea research. First, much dyspnea research is conducted on healthy individuals in laboratory settings; these data suggest that if the laboratory model is well chosen, such studies have relevance for our understanding of breathlessness associated with disease. Second, assessment of dyspnea has usually been limited to measurement within a single dimension such as intensity of a given, often non-specific, sensation. Our data argue that instruments such as the MDP can provide insight into affective as well as sensory experiences of dyspnea. The overall symptom burden of and functional limitation associated with clinical dyspnea may be heavily influenced by affective responses, and effective treatment of dyspnea, particularly in chronic disease, may depend upon manipulation of its affective components. Thus, the multidimensional assessment of both laboratory-evoked and naturally occurring dyspnea is an approach that can provide guidance for translating bench results to bedside application.

Endnotes

* Throughout the article the terms ‘unpleasantness’ and ‘discomfort’ are considered equivalent. While ‘Unpleasantness’ is more commonly used to describe the immediate affective response (A1) in multi dimensional models of pain, ‘Discomfort’ is employed in the ATS dyspnea statement.
13. Banzett RB, Adams L, O’Donnell CR, Gilman SA, Lansing RW, Schwartzstein RM: Using laboratory models to test treatment: morphine reduces dyspnea and hypercapnic ventilatory response. *Am J Respir Crit Care Med* 2011, 184:920–927.

14. Banzett RB, O’Donnell CR, Guilfoyle T, Lansing R, Schwartzstein RM: Is the experience of laboratory dyspnea different from wild-type dyspnea in COPD patients? [abstract]. *Am J Respir Crit Care Med* 2011, 183:A5810.

15. Meek PM, Banzaelt RB, Parshall MB, Gracely RH, Schwartzstein RM, Lansing RW: Reliability and validity of the multidimensional dyspnea profile (MDP). *Chest* 2012, 141(6):1546–1553.

16. Derogatis LR, Melisaratos N: *The brief symptom inventory: an introductory report*. *Psychol Med* 1983, 13:595–605.

17. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. [http://www.goldcopd.org/guidelines-global-strategy-for-diagnosis-management.html](http://www.goldcopd.org/guidelines-global-strategy-for-diagnosis-management.html).

18. Miller MR, Crapo R, Burgos F, Casaburi R, Coates A, Enright P, van der Grinten CP, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J. ATS/ERS Task Force: General considerations for lung function testing. *Eur Respir J* 2005, 26:153–161.

19. Revelette WR, Zecharman PW Jr, Parker DE, Wiley RL: Effect of background loading on perception of inspiratory loads. *J Appl Physiol* 1984, 56:404–410.

20. Bloch-Salisbury E, Shea SA, Brown R, Evans K, Banzaelt RB: Air hunger induced by acute increase in PCO2, adapts to chronic elevation of PCO2, in ventilated humans. *J Appl Physiol* 1996, 81(2):949–956.

21. Simon PM, Schwartzstein RM, Weiss JW, et al: Distinguishable types of dyspnea in patients with shortness of breath. *Am Rev Respir Dis* 1990, 142:1009–1014.

22. Schwartzstein RM, Simon PM, Weiss JW, et al: Breathlessness induced by dissociation between ventilation and chemical drive. *Am Rev Respir Dis* 1989, 139:1231–1237.

23. Schwartzstein R: The language of dyspnea. In *Dyspnea*. Edited by Mahler D. London: Marcel Dekker; 1998:35–62.

24. O’Donnell DE: Hyperinflation, dyspnea, and exercise tolerance in chronic obstructive pulmonary disease. *Proc Am Thor Soc* 2006, 3:180–184.

25. O’Donnell DE, Banzaelt RB, Carriere-Kohlman V, Casaburi R, Davenport PW, Gandevia SC, Gellb AF, Mahler DA, Webb KA: Pathophysiolog of dyspnea in chronic obstructive pulmonary disease: a roundtable. *Proc Am Thorac Soc* 2007, 4:145–169.

26. Binks AP, Vovk A, Fenigmo M, Banzaelt RB: The air hunger response of four elite breath-hold divers. *Respir Physiol Neurobiol* 2007, 159(2):171–177.

27. Krone HW: Individual differences in emotional reactions and coping. In *Handbook of affective sciences*. Edited by Davidson RJ, Scherer KR. Goldsmith HH. Oxford: Oxford University Press; 2003:698–728.

28. Allen SC, Vassallo M, Khattab A: The threshold for sensing airflow resistance during tidal breathing rises in old age: implications for elderly patients with obstructive airflow diseases. *Age Ageing* 2009, 38:548–552.

29. Allen SC, Khattab A: The airflow resistance sensing threshold during tidal breathing rises in old age in patients with asthma. *Age Ageing* 2012, 41:557–560.

30. Banzett RB, Lansing RW, Evans KC, Shea SA: Stimulus–response characteristics of CO2-induced air hunger in normal subjects. *Resp Physiol Neurobiol* 1996, 103:19–31.

doi:10.1186/1471-2466-13-27

Cite this article as: O’Donnell et al.: Dyspnea affective response: comparing COPD patients with healthy volunteers and laboratory model with activities of daily living. *BMC Pulmonary Medicine* 2013 13:27.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit